Cerezyme 400 U/10 ML

Packing : 400 U/10 ML

Generic Name : Imigluseraz

What is Cerezyme Used for and Cerezyme cost?

Cerezyme (Imiglucerase) is used to treat a genetic problem (Gaucher disease). Imiglucerase replaces a specific common substance (an enzyme called glucocerebrosidase) that is missing in people with Gaucher disease. This drug improves blood, bone, liver, and spleen issues brought by Gaucher sickness. Cerezyme cost and Cost of Cerezyme is low in India at Yourmedikart.store

Cerezyme is delivered by recombinant DNA technology using mammalian cell culture (Chinese hamster ovary). Purified imiglucerase is a monomeric glycoprotein of 497 amino acids, containing 4 Nlinked glycosylation sites (Mr = 60,430). Imiglucerase differs from placental glucocerebrosidase by one amino acid at position 495, where histidine is substituted for arginine. The oligosaccharide chains at the glycosylation sites have been adjusted to terminate in mannose sugars. The adjusted carbohydrate structures on imiglucerase are somewhat different from those on placental glucocerebrosidase. These mannose-terminated oligosaccharide chains of imiglucerase are specifically recognized by endocytic carb receptors on macrophages, the cells that accumulate lipid in Gaucher disease.

Cerezyme (imiglucerase for injection) is shown for long-term enzyme replacement treatment for pediatric and adult patients with a confirmed finding of Type 1 Gaucher disease that results in at least one of the following conditions:

• anemia (low red platelet check) thrombocytopenia (low blood platelet check)
• bone disease hepatomegaly or splenomegaly (enlarged liver or spleen)

Dosage And Administration

Cerezyme (imiglucerase for injection) is regulated by intravenous implantation more than 1-2 hours. Measurement should be individualized to every persistent. Introductory measurements range from 2.5 U/kg of body weight 3 times each week to 60 U/kg once every 2 weeks. 60 U/kg levery 2 weeks is the measurement for which the most information are available. Infection seriousness may direct that treatment be started at a generally high dose or moderately successive administration. Measurements changes should be made on an individual premise and may increase or decrease, in view of accomplishment of helpful objectives as surveyed by routine far reaching assessments of the patient’s clinical signs.

Cerezyme (imiglucerase for injection) is regulated by intravenous implantation more than 1-2 hours. Measurement should be individualized to every persistent. Introductory measurements range from 2.5 U/kg of body weight 3 times each week to 60 U/kg once every 2 weeks. 60 U/kg levery 2 weeks is the measurement for which the most information are available. Infection seriousness may direct that treatment be started at a generally high dose or moderately successive administration. Measurements changes should be made on an individual premise and may increase or decrease, in view of accomplishment of helpful objectives as surveyed by routine far reaching assessments of the patient’s clinical signs.

Cerezyme should be put away at 2-8°C (36-46°F). After reconstitution, Cerezyme should be investigated outwardly before use. Since this is a protein solution, slight flocculation (described as thin translucent fibers) happens sometimes after weakening. The weakened solution might be separated through an in-line low protein-restricting 0.2 μm filter during administration. Any vials showing misty particles or discoloration should not be used. Try not to USE Cerezyme after the termination date on the vial.

Cerezyme price in India is low. Buy Cerezyme infusion online at lowest price.

Important Safety Measures

Around 15% of patients have developed immune responses (antibodies) to Cerezyme during the main year of treatment. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been accounted for in under 1% of patients. Side effects suggestive of allergic reaction occurred in around 7% of patients, and include itching, flushing, hives, swelling, chest distress, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin because of reduced oxygen), and low pulse. If you have had a hypersensitive response to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

Hypertension in the arteries of the lungs (pulmonary hypertension) and pneumonia have been seen in under 1% of patients during treatment with Cerezyme. These are additionally known complications of Gaucher disease regardless of treatment. If you experience indications, for example, shortness of breath or chest pain, with or without fever, contact your doctor. Cerezyme price in India is low. Buy Cerezyme infusion online at lowest price.

Roughly 14% of patients have experienced side effects identified with treatment with Cerezyme. A portion of these reactions happen at the site of injection like discomfort, itching, burning, swelling or uninfected abscess. Other side effects, every one of which was accounted for by under 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Cerezyme cost and Cost of Cerezyme is low in India at Yourmedikart.store

Indications

Long-term enzyme replacement therapy for patients with confirmed type 1 Gaucher disease, resulting in one or more of the following conditions: 1) Anemia; 2) Thrombocytopenia; 3) Bone disease; 4) Hepatomegaly or splenomegaly.

Adults and Children

<2 years old: not recommended. ≥2 years: intravenous infusion for 1 to 2 hours. Personalize. The starting dose range: 2.5 units/kg three times a week to 60 units/kg once every two weeks.

Warnings and Precautions

Regularly monitor the formation of IgG antibodies during the first year. Patients who have previously been treated with Ceredase (arabinase injection) and have developed antibodies or allergies to Ceredase. Control pulmonary hypertension and pneumonia. Pregnancy (Category C). Nursing mother.

Side Effects

Since the approval of Cerezyme (imiglucerase for injection) in May 1994, Genzyme has maintained a worldwide post-marketing database of spontaneously reported adverse events and adverse events discussed in the medical literature. The percentage of events for each reported adverse reaction term has been calculated using the number of patients from these sources as the denominator for total patient exposure to Cerezyme since 1994. Actual patient exposure is difficult to obtain due to the voluntary nature of the database and the continuous accrual and loss of patients over that span of time. The actual number of patients exposed to Cerezyme since 1994 is likely to be greater than estimated from these voluntary sources and, therefore, the percentages calculated for the frequencies of adverse reactions are most likely greater than the actual incidences.

Experience in patients treated with Cerezyme has revealed that approximately 13.8% of patients experienced adverse events which were judged to be related to Cerezyme administration and which occurred with an increase in frequency. Some of the adverse events were related to the route of administration. These include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Each of these events was found to occur in < 1% of the total patient population.

Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of patients. Onset of such symptoms has occurred during or shortly after infusions; these symptoms include pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Anaphylactoid reaction has also been reported. Each of these events was found to occur in < 1.5% of the total patient population. Pre-treatment with antihistamines and/or corticosteroids and reduced rate of infusion have allowed continued use of Cerezyme in most patients.

Additional adverse reactions that have been reported in approximately 6.5% of patients treated with Cerezyme include: nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Each of these events was found to occur in < 1.5% of the total patient population.

FAQ